Found 43 Enz. Inhib. hit(s) with all data for assayid = 1 entry = 831 TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 300nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 500nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 700nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 800nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 800nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 900nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 900nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 900nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.20E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.50E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.60E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 2.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 2.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 2.20E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 2.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 2.50E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 2.70E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 3.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 3.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 3.80E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 4.60E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 4.70E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 5.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 6.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 6.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 2.30E+4nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 3.10E+4nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 5.02E+6nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.00E+7nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals, Inc.
US Patent
Longevica Pharmaceuticals, Inc.
US Patent
Affinity DataIC50: 1.00E+7nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
